Contact
![Contact Meredith Alda](https://cdn.statcdn.com/contactPerson/3646.jpg)
Mon - Fri, 9am - 6pm (EST)
![Contact Yolanda Mega](https://cdn.statcdn.com/contactPerson/3195.jpg)
Mon - Fri, 9am - 5pm (SGT)
![Contact Kisara Mizuno](https://cdn.statcdn.com/contactPerson/2661.jpg)
Mon - Fri, 10:00am - 6:00pm (JST)
![Contact Lodovica Biagi](https://cdn.statcdn.com/contactPerson/863.jpg)
Mon - Fri, 9:30am - 5pm (GMT)
![Contact Carolina Dulin](https://cdn.statcdn.com/contactPerson/3012.jpg)
Mon - Fri, 9am - 6pm (EST)
Key regions: Australia, Italy, France, South Korea, Brazil
The Caribbean region has been steadily developing its Vaccines market in recent years, with a focus on improving access to essential vaccines for its population.
Customer preferences: Customers in the Caribbean region are increasingly prioritizing access to affordable and effective vaccines, particularly for diseases that are prevalent in the region such as dengue fever and chikungunya. Additionally, there is a growing demand for vaccines that protect against emerging infectious diseases such as Zika virus.
Trends in the market: One of the key trends in the Caribbean Vaccines market is the increasing availability of combination vaccines, which offer protection against multiple diseases in a single shot. This is particularly important in the Caribbean region, where there is a high prevalence of multiple infectious diseases. Additionally, there is a growing trend towards the use of vaccines that are more easily administered, such as oral vaccines and those that require fewer doses.
Local special circumstances: The Caribbean region faces several unique challenges in the Vaccines market, including limited healthcare infrastructure in some areas and a lack of access to vaccines in certain populations. Additionally, there is a need for greater education and awareness around the importance of vaccination, particularly in rural and remote areas.
Underlying macroeconomic factors: The development of the Vaccines market in the Caribbean region is closely tied to broader macroeconomic factors, including government investment in healthcare infrastructure and the availability of funding for vaccine research and development. Additionally, the region's vulnerability to infectious diseases and the potential impact on tourism and other key industries has led to increased investment in vaccine development and distribution.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)